Winfried Rief

from Wikipedia, the free encyclopedia

Winfried Rief (born May 12, 1959 ) is a German psychologist. Since 2000 he has been professor for clinical psychology and psychotherapy at the Philipps University of Marburg . There he established the University Outpatient Clinic for Psychotherapy (Psychotherapy Ambulance Marburg, PAM), the Institute for Psychotherapy Training Marburg (IPAM) and heads the Department of Clinical Psychology and Psychotherapy.

Life

Rief studied psychology at the University of Trier (1979–1984). He then worked at the research station of the University of Konstanz at the Reichenau State Psychiatric Hospital, where he received his doctorate in 1987 on the subject of "Information processing in schizophrenics". He obtained his habilitation in 1994 at the University of Salzburg on the subject of "Somatoform disorders and hypochondria". This was followed by clinical activities at the Rottweil Psychiatric Hospital (1986–1987) and at the Roseneck Medical-Psychosomatic Clinic (Prien am Chiemsee), where he worked as a senior psychologist from 1989.

In 2000, Rief accepted a professorship for clinical psychology and psychotherapy at the University of Marburg . In the next few years he was visiting professor at Harvard Medical School in Boston (2004–2005), the University of California in San Diego (2009/2010), and the University of Auckland in New Zealand (2002). Rief is the spokesman for the “Psychology and Psychotherapy Training” commission of the German Psychological Society (DGPs). He was also president of the German Society for Behavioral Medicine (2001–2005) and a member of the expert commission of the American Psychiatric Association (APA) and World Health Organization (WHO) "Somatic Presentations of Mental Disorders" in preparation for DSM-5 (Beijing, 2006 ). In addition, he is spokesman for the DFG research group on placebo and nocebo mechanisms (2010–2019), DFG review board (2012–2020), member of the DFG commission “Clinical Studies” and co-chair of the ICD-11 working group "Classification of Chronic Pain" of the WHO (since 2013). He is editor in chief of the journal "Clinical Psychology in Europe" [cpe.psychopen.eu] and board member of the European Association of Clinical Psychology and Psychological Treatment EACLIP [eaclipt org]. Rief was named a Distinguished International Affiliate, APA Health Psychology Division in 2014 and was named a Distinguished Scientist by the International Society of Behavioral Medicine in 2014.

plant

For many years, Rief's scientific work focused on the investigation of psychological factors in the development, maintenance and management of physical complaints. He researches " somatoform disorders ". Together with Prof. Hiller (Mainz) he developed the questionnaire procedure SOMS (screening for somatoform disorders). As a nominated member of the initial group for reformulating the concept of somatoform disorders in DSM-5, he initially participated in this process, but later also clearly criticized the concept of "somatic stress disorders" presented in DSM-5 in 2014.

In 2009, the German version of ICD-10 introduced the new diagnosis F45.41 "Chronic pain with psychological and somatic factors" [Rief et al. in Current Opinion of Psychiatry]. This introduction was made by a working group led by Rief. As co-chair together with R.-D. Treede, he also led the working group on the classification of chronic pain in ICD-11. The classification proposal of this working group for chronic pain was officially adopted by the World Health Assembly 2019 in the draft for ICD-11 [icd.who.int], which will become the basis for the classification of physical and mental illnesses worldwide.

Since 2004 he has expanded his research focus to include the subject of “placebo and nocebo mechanisms in medical interventions” and has been leading a corresponding supraregional DFG research group since 2010 (DFG 1328). He was able to prove that the expectations of the patients contributed significantly to the success of the treatment, even in the case of very invasive medical interventions (such as cardiac surgery), and a modification of these patient expectations increases the success of such measures. But patient expectations are also essential for the development of side effects.

In professional policy terms, Rief has been advocating a revision of the Psychotherapists Act to align it with the training and further education structure of medical health professions since 2011, as spokesman for the “Psychology and Psychotherapy Training ” commission, which is commissioned by the German Society for Psychology (DGPs) and the Psychology Faculty Conference . The law was passed by the German Bundestag in September 2019 (PsychThGAusbRefG). In addition, he has been involved in the promotion of young talent within clinical psychology since around 2005 . He developed the so-called “Marburg model” to combine the doctoral phase and clinical training in psychotherapy.

Rief was also part of the initiative group to found a European Society for Clinical Psychology and is a board member of the European Association of Clinical Psychology and Psychological Treatment [eaclipt.org]. As Editor in Chief, he launched the journal “Clinical Psychology in Europe”, an open access journal that aims to promote new developments in the field of open science and does not require article processing charges [cpe.psychopen.eu].

Publications

  • U. Bingel (for the Placebo Competence Group: U. Bingel, P. Enck, W. Rief, M. Schedlowski): Avoiding nocebo effects to optimize treatment outcome. In: JAMA. 312, 2014, pp. 693-694.
  • P. Enck, U. Bingel, M. Schedlowski, W. Rief: Minimize, maximize, or personalize? - What to do with the placebo response in medicine? In: Nature Review Drug Discovery. Vol. 12, 2013, pp. 191-204.
  • K. Petrie, T. Müller, F. Schirmbeck, L. Donkin, E. Broadbent, CJ Ellis, G. Gamble, W. Rief: Effect of providing information about normal test results on patients' reassurance: randomized controlled trial. In: British Medical Journal. 334, 2007, pp. 352-354.
  • W. Rief, N. Birbaumer (Ed.): Biofeedback. Basics, indication, communication and practical approach in therapy. 3. Edition. Schattauer-Verlag, Stuttgart 2010.
  • W. Rief, E. Broadbent: Explaining medically unexplained symptoms- Models and mechanisms. In: Clinical Psychology Review. 27, 2007, pp. 821-841.
  • W. Rief, JA Glombiewski: The hidden effects of blinded, placebo controlled randomized trials: An experimental investigation. In: Pain. 153, 2012, pp. 2473-2477.
  • W. Rief, P. Henningsen (Ed.): Psychosomatics and behavioral medicine. Schattauer-Verlag, Stuttgart 2015.
  • W. Rief, W. Hiller: The Screening for Somatoform Disorders SOMS. Manual for the questionnaire. 2., revised. Edition. Huber-Verlag, Bern 2008.
  • W. Rief, A. Martin: How to use the new DSM-5 diagnosis Somatic Symptom Disorder in research and practice? - A critical evaluation and a proposal for modifications. In: Annual Review of Clinical Psychology. 10, 2014, pp. 339-67.
  • W. Rief, J. Avorn, AJ Barsky: Medication-attributed adverse effects in placebo groups. Implications for assessment of adverse effects. In: Archives of Internal Medicine. 166 (2), 2006, pp. 155-160.
  • W. Rief, AJ Barsky, U. Bingel, B. Doering, R. Schwarting, M. Wöhr, U. Schweiger: Rethinking psychopharmacotherapy: The role of treatment context and brain plasticity in antidepressant and antipsychotic interventions. In: Neuroscience & Biobehavioral Reviews. 60, 2016, pp. 51-64. doi: 10.1016 / j.neubiorev.2015.11.008 .
  • W. Rief, U. Bingel, M. Schedlowski, P. Enck: Mechanisms involved in placebo and nocebo responses and implications for drug trials. In: Clinical Pharmacology & Therapeutics. 90, 2011, pp. 722-726.
  • W. Rief, AM Heitmüller, K. Reisberg, H. Rüddel: Why reassurance fails in patients with unexplained symptoms - An experimental investigation of remembered probabilities. In: PLoS Medicine. 3 (8), 2006, p. E269. doi: 10.1371 / journal.pmed.0030269 .
  • W. Rief, S. Kaasa, R. Jensen, S. Perrot, JWS Vlaeyen, R.-D. Treede, KCP Vissers: The need to revise pain diagnoses in ICD-11. In: Pain. 149, 2010, pp. 169-170.
  • M. Schedlowski, P. Enck, W. Rief, U. Bingel: Neuro-Bio-Behavioral Mechanisms of Placebo and Nocebo Responses: Implications for Clinical Trials and Clinical Practice. In: Pharmacological Review. 67, 2015, pp. 697-730.
  • C. Seifart, M. Hofmann, T. Bär, J. Riera, U. Seifart, W. Rief: Breaking bad news - what patients want and what they get. Evaluating the SPIKES protocol in Germany. In: Annals of Oncology. 25, 2014, pp. 707-711.
  • R.-D. Treede, W. Rief, A. Barke, Q. Aziz, MI Bennett, R. Benoliel, M. Cohen, S. Evers, NB Finnerup, MB First, MA Giamberardino, S. Kaasa, E. Kosek, P. Lavandʼhomme, M. Nicholas, S. Perrot, J. Scholz, S. Schug, BH Smith, P. Svensson, JWS Vlaeyen, S.-J. Wang: A classification of chronic pain for ICD-11. In: Pain. 156 (6), 2015, pp. 1003-1007 (shared first authorship of Treede, Rief & Barke).

Web links

Individual evidence

  1. Called CV
  2. ^ Rief, W. & Hiller, W. (2008). The Screening for Somatoform Symptoms [The Screening for Somatoform Symptoms]. Manual for the questionnaire. Bern: Huber-Verlag. 2nd revised edition.
  3. ^ W. Rief, A. Martin: How to use the new DSM-5 diagnosis Somatic Symptom Disorder in research and practice? - A critical evaluation and a proposal for modifications. In: Annual Review of Clinical Psychology. 10, 2014, pp. 339-67
  4. Winfried Rief, Meike C. Shedden-Mora, Johannes AC Laferton, Charlotte Auer, Keith J. Petrie, Stefan Salzmann, Manfred Schedlowski & Rainer Moosdorf: Preoperative optimization of patient expectations improves long-term outcome in heart surgery patients: results of the randomized controlled PSY-HEART trial, BMC Medicine volume 15, Article number: 4 (2017)
  5. ^ Petrie KJ, Rief W .: Psychobiological Mechanisms of Placebo and Nocebo Effects: Pathways to Improve Treatments and Reduce Side Effects. Annu Rev Psychol. 2019 Jan 4; 70: 599-625.
  6. Bundestag law archive